Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 Ash Annual Meeting

THOMSON REUTERS
10 Dec 2024

Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 Ash Annual Meeting

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10